Liraglutide
SAXAPCOS
Novo Nordisk · Phase 3 · Completed · Enrollment 88
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Liraglutide Pen Injector (Saxenda) | 14 participants | 5 participants | 4 participants | n/r | 0 |
| Placebo liraglutide pen injector | 3 participants | 0 participants | 0 participants | n/r | 0 |
A count stays a count. This page does not turn a count into a percent.